Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients

Journal of Pharmacology and Experimental Therapeutics

Volumn 326, Issue 2, 2008, Pages 555-562

  Marathe, Anshu ^a   Peterson, Mark C ^b   Mager, Donald E ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; DENOSUMAB;

ARTICLE; CELL INTERACTION; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG RESPONSE; HOMEOSTASIS; HUMAN; MULTIPLE MYELOMA; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PHARMACODYNAMICS; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BONE AND BONES; BONE RESORPTION; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HOMEOSTASIS; HUMANS; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; PEPTIDES; RANK LIGAND;

EID: 47949113939     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.137703     Document Type: Article

References (27)

1. Aubin JE and Bonnelye E (2000) Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos Int 11:905-913.
2. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, and DePaoli AM (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059-1066.
3. Body JJ, Facon T, Coleman RE, Lipton A, Geurs F, Fan M, Holloway D, Peterson MC, and Bekker PJ (2006) A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12:1221-1228.
4. Boyle WJ, Simonet WS, and Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337-342.
5. D'Argenio DZ and Schumitzky A (1997) ADAPT II user's guide, in Biomedical Simulation Resource, Los Angeles, CA.
6. Dayneka NL, Garg V, and Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478.
7. Filvaroff E and Derynck R (1998) Bone remodelling: a signalling system for osteoclast regulation. Curr Biol 8:R679-R682.
8. Heider U, Langelotz C, Jakob C, Zavrski I, Fleissner C, Eucker J, Possinger K, Hofbauer LC, and Sezer O (2003) Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 9:1436-1440.
9. Hideshima T, Mitsiades C, Tonon G, Richardson PG, and Anderson KC (2007) Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer 7:585-598.
10. Hideshima T, Richardson P, and Anderson KC (2003) Novel therapeutic approaches for multiple myeloma. Immunol Rev 194:164-176.
11. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, and Riggs BL (2000) The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12.
12. Iqbal J, Sun L, Kumar TR, Blair HC, and Zaidi M (2006) Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proc Natl Acad Sci U S A 103:14925-14930.
13. Komarova SV, Smith RJ, Dixon SJ, Sims SM, and Wahl LM (2003) Mathematical model predicts a critical role for osteoclast autocrine regulation in the control of bone remodeling. Bone 33:206-215.
14. Kostenuik PJ (2005) Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5:618-625.
15. Kyle RA and Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860-1873.
16. Lemaire V, Tobin FL, Greller LD, Cho CR, and Suva LJ (2004) Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. J Theor Biol 229:293-309.
17. Lobo ED, Hansen RJ, and Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645-2668.
18. Mager DE and Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507-532.
19. Mager DE and Krzyzanski W (2005) Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm Res 22:1589-1596.
20. Martin MJ and Buckland-Wright JC (2004) Sensitivity analysis of a novel mathematical model identifies factors determining bone resorption rates. Bone 35:918-928.
21. Matsumoto T and Abe M (2006) Bone destruction in multiple myeloma. Ann N Y Acad Sci 1068:319-326.
22. Peterson MC and Riggs MM (2007) Calcium homeostasis and bone remodeling: development of an integrated model for evaluation and simulation of therapeutic responses to bone-related therapies. PAGE (Population Approach Group in Europe) Sixteenth Meeting; 2007 Jun 13-15; Copenhagen, Denmark. PAGE, Copenhagen, Denmark.
23. Roodman GD (1999) Cell biology of the osteoclast. Exp Hematol 27:1229-1241.
24. Schwarz EM, Keefe O, Regis J, Lianping X, Looney JR, and Ritchlin CT (2005) Receptor activator of nuclear κb ligand and osteoprotegrin: where are we now and what about future treatment uses? Curr Opin Orthopaed 16:370-375.
25. Schwarz EM and Ritchlin CT (2007) Clinical development of anti-RANKL therapy. Arthritis Res Ther 9 (Suppl 1):S7.
26. Sezer O, Heider U, Jakob C, Eucker J, and Possinger K (2002) Human bone marrow myeloma cells express RANKL. J Clin Oncol 20:353-354.
27. Sharma A and Jusko WJ (1998) Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol 45:229-239.